** India's third-largest drugmaker by sales, Cipla CIPL.NS reported quarterly profit that beat analysts' estimates on higher domestic demand for its generic respiratory drugs
** Shares climbed 2% on the day after rising about 3% post results on Friday
** At least 14 brokerages hiked price targets on the stock after earnings, raising the median PT to 1,723.5 rupees from 1,675 rupees last month, as per data compiled by LSEG
LINE-UP OF KEY LAUNCHES IN THE U.S. TO DRIVE GROWTH
** HSBC ("buy," PT: 1,740 rupees) says decline in Cipla's sales of generic cancer drug gRevlimid is imminent in FY26
** Adds, a good line-up of differentiated launches in the U.S. likely to offset the weakness
** Goldman Sachs ("sell," PT: 1,375 rupees) expects Cipla to rely heavily on new launches for growth in the United States
** Jefferies ("hold," PT: 1,690 rupees) says growth in key U.S. market disappointed, but launches in the market will start reflecting in Cipla's growth from H2FY27 onwards
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.